Mary Jane Plym

Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine

Daniel J. Tenney, Steven M. LeVine, R.E. Rose et al. · Antimicrobial Agents and Chemotherapy · 2004 · 538 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17

Entecavir resistance is rare in nucleoside naïve patients with hepatitis B

Richard J. Colonno, Ronald E. Rose, Carl J. Baldick et al. · Hepatology · 2006 · 348 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17

Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present

Daniel J. Tenney, Ronald E. Rose, Carl J. Baldick et al. · Antimicrobial Agents and Chemotherapy · 2006 · 239 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17

A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo

Armen B. Shanafelt, Yue Lin, Marie-Claude Shanafelt et al. · Nature Biotechnology · 2000 · 133 citations

Life Sciences, Immunology, Oncology +14

BL-1249 [(5,6,7,8-Tetrahydro-naphthalen-1-yl)-[2-(1 H-tetrazol-5-yl)-phenyl]-amine]: A Putative Potassium Channel Opener with Bladder-Relaxant Properties

Svetlana Tertyshnikova, Ronald J. Knox, Mary Jane Plym et al. · Journal of Pharmacology and Experimental Therapeutics · 2005 · 57 citations

Natural Sciences, Pharmacology, Physiology +17